WHO Expert Committee on Selection and Use of Essential Medicines - WHO Technical Report Series, No. 850, Annex 3 (Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products) - Sixth Report
(1995; 36 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoINTRODUCTION
Ver el documentoGLOSSARY
Abrir esta carpeta y ver su contenido1. PROVISIONS AND PREREQUISITES FOR A CLINICAL TRIAL
Ver el documento2. THE PROTOCOL
Abrir esta carpeta y ver su contenido3. PROTECTION OF TRIAL SUBJECTS
Abrir esta carpeta y ver su contenido4. RESPONSIBILITIES OF THE INVESTIGATOR
Cerrar esta carpeta5. RESPONSIBILITIES OF THE SPONSOR
Ver el documento5.1 Selection of the investigator(s)
Ver el documento5.2 Delegation of responsibilities
Ver el documento5.3 Compliance with the protocol and procedures
Ver el documento5.4 Product information
Ver el documento5.5 Safety information
Ver el documento5.6 Investigational product
Ver el documento5.7 Trial management and handling of data
Ver el documento5.8 Standard operating procedures
Ver el documento5.9 Compensation for subjects and investigators
Ver el documento5.10 Monitoring
Ver el documento5.11 Quality assurance
Ver el documento5.12 Study reports
Ver el documento5.13 Handling of adverse events
Ver el documento5.14 Termination of trial
Abrir esta carpeta y ver su contenido6. RESPONSIBILITIES OF THE MONITOR
Abrir esta carpeta y ver su contenido7. MONITORING OF SAFETY
Abrir esta carpeta y ver su contenido8. RECORD KEEPING AND HANDLING OF DATA
Abrir esta carpeta y ver su contenido9. STATISTICS AND CALCULATIONS
Abrir esta carpeta y ver su contenido10. HANDLING OF AND ACCOUNTABILITY FOR PHARMACEUTICAL PRODUCTS
Abrir esta carpeta y ver su contenido11. ROLE OF THE DRUG REGULATORY AUTHORITY
Ver el documento12. QUALITY ASSURANCE FOR THE CONDUCT OF A CLINICAL TRIAL
Ver el documento13. CONSIDERATIONS FOR MULTICENTRE TRIALS
Ver el documentoREFERENCES
Ver el documentoAPPENDIX 1: World Medical Association’s Declaration of Helsinki1
Ver el documentoAPPENDIX 2: Model list of items to be contained in a clinical trial protocol
 

5.6 Investigational product

The sponsor is responsible for supplying the investigational pharmaceutical product(s) and, if applicable, comparator products, prepared in accordance with principles of Good Manufacturing Practice (GMP) (see also Section 10). The product(s) should be fully characterized, properly coded, and suitably packaged in such a way as to provide protection against deterioration and safeguard blinding procedures (if applicable); appropriate investigational labelling should be affixed.

Sufficient samples of each batch and a record of analyses and characteristics must be kept for reference so that, if necessary, an independent laboratory is able to re-check the investigational product(s), e.g. for quality control or bioequivalence.

Records of the quantities of investigational pharmaceutical products supplied must be maintained with batch or serial numbers. The sponsor must ensure that the investigator is able to establish a system within his or her institution for adequate and safe handling, storage, use, return (to the investigator or sponsor) and, if appropriate, destruction of the investigational product(s).

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013